Key Takeaways:

  • Analysts say a breakthrough pancreatic cancer drug developed by Revolution Medicines, with its higher-than-expected pricing, is likely to quickly become a blockbuster and eventually rank among the world's best-selling drugs.
  • Revolution announced that the 30-day course of the drug, Rasonque, is priced at $39,800, significantly higher than the $25,000 to $30,000 some analysts had previously expected. Based on this, its annual acquisition cost (wholesale acquisition cost) would exceed $477,000,more than double the list price of Keytruda, Merck & Co.'s best-selling cancer drug worldwide.。
  • Given the price and the promising label indication, analysts at Evercore ISI raised their sales forecast for Rasonque in pancreatic cancer alone to $2.4 billion next year, reaching $15.1 billion by 2034. Evercore also expects the drug tobe approved for other types of cancer, with peak annual revenue potentially reaching $20.8 billion.

In-Depth Analysis:

Followinga lightning-fast approval from the U.S. Food and Drug Administration (FDA), Revolution is fully committed to launching and promoting the drug to ensure it lives up to expectations. The company began offering the once-daily oral tablet immediately on Wednesday (the day of approval) and established a patient assistance program called (ON)Path to help patients navigate insurance, find financial aid, and manage side effects.

"Rasonque has the elements to become one of the fastest-launching drugs in oncology history, or possibly the fastest ever," Evercore analyst Cory Kasimov wrote in a note to clients. In another note following the company's conference call, he added that Rasonque's launch "will be transformative and historic, and the label and pricing details further reinforce our conviction."

The FDA approved Rasonque for patients with metastatic pancreatic adenocarcinoma who have received one prior systemic therapy, or who are not suitable for "multi-agent systemic therapy." Analysts noted that the word "or" in the label is crucial, providing flexibility for doctors to use it as a first-line treatment.

RBC Capital Markets analyst Leonid Timashev predicted in a note to clients that some insurers may attempt to restrict the drug's use as a first-line therapy due to its high cost, but friction with payers overall will be limited because many patients lack other treatment options. He also wrote that Revolution is likely to move quickly to advance the drug's approval in the first-line setting. Currently, aPhase III clinical trial for first-line treatmentis underway.

Rasonque represents ascientificandmedicaldual breakthrough: it successfully targets a target once considered "undruggable" and extends survival in patients with this highly lethal tumor. The FDA approved the drug just over a month after Revolution submitted its application, and in the agency's press release, an official evencalled the efficacy results "unprecedented"。

Despite the drug's significant side effects, doctors and patients are excited about its ability to attack tumors and extend survival. Patients who have benefited from the drug include former U.S. Senator Ben Sasse, a Nebraska Republican, whoshared his treatment experience with The New York Times。